SARC038: A Phase 2 Study of Regorafenib in Combination With Nivolumab in Patients With Refractory or Recurrent Osteosarcoma
Latest Information Update: 29 Mar 2023
At a glance
- Drugs Nivolumab (Primary) ; Regorafenib (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 23 Mar 2023 Status changed from recruiting to active, no longer recruiting.
- 19 Jan 2023 Planned primary completion date changed from 1 Dec 2022 to 1 May 2024.
- 11 Jun 2021 Status changed from not yet recruiting to recruiting.